Equities

BioNexus Gene Lab Corp

BGLC:NAQ

BioNexus Gene Lab Corp

Actions
Basic MaterialsIndustrial Materials
  • Price (USD)0.544
  • Today's Change-0.002 / -0.44%
  • Shares traded59.40k
  • 1 Year change-85.74%
  • Beta1.8788
Data delayed at least 15 minutes, as of May 23 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioNexus Gene Lab Corporation is a Malaysia-based company, which provides ribonucleic acid (RNA)-based genomic diagnostics. The Company provides a molecular lab that is focused on the application of functional genomics to enable early detection of infectious diseases and cancers. The Company operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex. MRNA Scientific Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which the Company uses in its business. The Company's non-invasive blood screening tests analyze changes in RNA to coronavirus, dengue, human immunodeficiency virus (HIV), human papillomavirus (HPV) and the risk potentiality of cancer diseases. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region.

  • Revenue in USD (TTM)9.78m
  • Net income in USD-2.66m
  • Incorporated2017
  • Employees30.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CV Sciences Inc15.86m-3.23m8.98m42.00--3.80--0.5661-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
BioRestorative Therapies Inc145.80k-14.42m9.07m11.00--0.5468--62.22-3.54-3.540.03462.450.01--8.2613,254.55-99.26-199.86-104.68-334.04-----9,887.16-19,887.03----0.00--21.705.6122.06--67.77--
Weed Inc0.00-5.19k9.08m2.00--84.45231.77---0.00001-0.000010.000.00090.00----0.00-0.4942-385.93-9.56-822.37-----------23.030.5461------97.93---59.13--
Pacific Software Inc0.00-77.46k9.36m0.00--0.3008-----0.1832-0.18320.000.76460.00-------26.19-620.48-66.38-------------6.290.00-------13.29------
Ayala Pharmaceuticals Inc13.00k-48.07m9.38m20.00------721.49-7.46-7.460.0022-2.06------650.00--------0.00---369,784.60-----2.31----------------
Endexx Corp4.64m6.93m9.53m--1.42--1.612.060.01330.01330.0091-0.02550.67734.3713.54--86.51------28.73--127.74--0.0664------228.66--28.26------
Transcode Therapeutics Inc0.00-17.06m9.54m10.00--1.82-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Chromocell Therapeutics Corp0.00-8.98m9.57m4.00--8.47-----1.66-1.660.000.1960.00----0.00-440.01-----------------7.200.00-------200.20------
Enzon Pharmaceuticals Inc0.00221.00k9.64m0.0043.572.93----0.0030.0030.000.6240.00------3.21-0.86543.24-0.8851-------159.43----0.00---100.00--106.71-55.86----
BioNexus Gene Lab Corp9.78m-2.66m9.65m30.00--1.03--0.9875-0.14-0.140.6510.52891.018.555.80---27.53-3.83-33.16-5.0213.5614.55-27.25-3.043.98-162.450.00---10.60115.07-638.56--30.40--
Protext Mobility Inc750.00-2.21m9.67m4.00------12,893.79-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Vaxxinity Inc0.00-56.94m9.78m57.00--0.7288-----0.4499-0.44990.000.10580.00----0.00-75.56---111.46--------------0.5308------24.31------
Galera Therapeutics Inc0.00-45.75m10.10m7.00---------0.9971-0.99710.00-2.480.00----0.00-115.30-83.69-142.79-97.54-----------6.499.23------5.05---29.84--
Kintara Therapeutics Inc0.00-9.51m10.18m2.00---------4.08-4.080.000.10710.00----0.00-131.55-220.94-185.60-329.97------------0.00------40.24--78.93--
Data as of May 23 2024. Currency figures normalised to BioNexus Gene Lab Corp's reporting currency: US Dollar USD

Institutional shareholders

0.45%Per cent of shares held by top holders
HolderShares% Held
Virtu Americas LLCas of 31 Dec 202326.15k0.15%
Geode Capital Management LLCas of 31 Mar 202423.68k0.13%
HRT Financial LLCas of 31 Mar 202421.90k0.12%
UBS Securities LLCas of 31 Mar 20248.42k0.05%
Citadel Securities LLCas of 31 Mar 20240.000.00%
Tower Research Capital LLCas of 31 Mar 20240.000.00%
Two Sigma Securities LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.